Genovis expands its patent portfolio - patent granted in South Korea

Genovis, a Swedish company that develops and markets innovative tools for medical
research using its internally developed and patented NIMT™ (NanoInducedMagnetic-
Transfer) technology, has been granted a new patent in South Korea.

Genovis has been granted a patent by the Korean Intellectual Property Office. The patent has
already been approved within the EU (EPO) and in Australia, plus international applications are
also pending in Japan and countries in North and South America respectively. The patent
describes the technical foundation behind the NIMT™ technology and will remain in force until
2019.
- “South Korea is part of the rapidly growing Asian market for biotechnology and
pharmaceutical production. National research programs, increased funds for research
grants and new production facilities are among the current targets of substantial
investment activity,” says Sarah Fredriksson, the CEO of Genovis. “It thus is quite natural
for Genovis to secure a patent there, as well as in other interesting markets.”